Phase II trial of monoclonal antibody J591 in combination with low-dose interleukin-2 [aldesleukin] in patients with recurrent prostate cancer

Trial Profile

Phase II trial of monoclonal antibody J591 in combination with low-dose interleukin-2 [aldesleukin] in patients with recurrent prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2007

At a glance

  • Drugs Aldesleukin; J 591
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top